Anti-DLL3 antibody drug conjugates for treating cancer
US10478509B2 · kind B2 · utility
5Cited by
77References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 5, 2018 |
| Grant date | Nov 19, 2019 |
| Priority date | — |
| Expiry date | May 1, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.